QUERY CONTROL	FORM	-		RTIS U	SE ONLY
Application No.	10/067996	Prepared by	ewc	Tracking Number	05951/25
Examiner-GAU	Habte	Date	10.2609	Week Date	5-17-04
	1624	No. of queries	- 2 -	IFW	

2nd request

JACKET							
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449				
b. Applicant(s)	g. Disclaimer	I. Print Fig.	q. PTOL-85b				
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract				
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs				
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other				

SPECIFICATION	MESSAGE
a. Page Missing	is Please provide is sving classification form,
b. Text Continuity	NOA and PTO-37 form.
c. Holes through Data	2) PTO-1449 Please either initial or line
d. Other Missing Text	through citations on IDS of 4-12.04
e. Illegible Text	ore attached copies
f. Duplicate Text	Thank you
g. Brief Description	οωί
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	
d. Incorrect Numbering	initials
e. Index Disagrees	RESPONSE
f. Punctuation	
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other	
	initials

Appr. .-d for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Spstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	 of	2

	Complete if Known	
Application Number	10/067,996	
Filing Date	February 8, 2002	
First Named Inventor	Allen T. Hopper	
Group Art Unit	Unassgined	
Examiner Name	Unassigned	
Attorney Docket Number	MEMORY-2	

			U.S. PATENT DOCUM	MENTS	
Examinar Initials	·Cite No.	U.S. Patent Document Kind Code ² Number (if known)	Name of Patenties or Applicant of Cited Document	Oate of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	3,917,583	Meyer et al	11-04-1975	
	A2	3,919,192	Meyer et al.	11-11-1975	
	A3	5,744,473	Chasin et al.	. 04-28-1998	
	A4	5,814,651	Ouplantier et al.	09-29-1998	•
	A5	5,864,037	Chasin et al.	01-26-1999	
	AB	5,935,978	Fenton et al.	08-10-1999	
	A7	5,939,422	Cavalla et al.	08-17-1999	·
	A8	8,037,470	Cavalla et al.	03-14-2000	
	A9	6,040,447	Cavalia et al.	03-21-2000	
	A10	6,057,445	Cavalla et al.	05-02-2000	
······	A11	6,211,367	Cavalla et al.	04-03-2001	
	A12	6,228,859	Cavalla et al.	05-08-2001	
	A13	6,310,205	Chasin et al.	10-30-2001	
	A14	6,318,928	Chasin et al.	11-20-2001	
				· · · · · · · · · · · · · · · · · · ·	
					·
					

	·		FOR	REIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Fore Office ³	eign Patent Document Number Kind Co	ode ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т,
	A15	DE	2 405 895			08-29-1974		
	A16	DE	42 30 755	$\neg \neg$		03-17-1994		
	·A17	DE	197 02 785	$\neg \neg$		07-30-1998		
	A18	DE	199 35 209			02-08-2001		
	A19	JP	62-10085			01-19-1987		
	A20	JP	10-72415			03-17-1998		
	A21	JP	11-180982			07-06-1999		
	A22	JP	11-189577			07-13-1999		
	A23	JP.	2000-72773			03-07-2000		
	A24	WIPO	WO 93/25517			12-23-1993		
	A25	WIPO	WO 94/14742			. 07-07-1994		
	A26	WIPO	WO 98/58901			12-30-1998		
	A27	WIPO	WO99/24432			05-20-1999		
	A28	WIPO	WO 99/29694			06-17-1999		
	A29	WIPO	WO 01/87281	$\neg \neg$		11-22-2001		

Examiner Signature	Date Considered	

EXAMINER: tritial if reterance considered, whether or not chation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See strached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emporer must precode the script number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a vaid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/067,996 INFORMATION DISCLOSURE Filing Date February 8, 2002 STATEMENT BY APPLICANT First Named Inventor Allen T. Hopper Group Art Unit Unassgined (use as many sheets as necessary) Examiner Name Unassigned : of 2 Sheet Attorney Docket Number MEMORY-2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 3
_	A30	THOMAS C. MCKENZIE et al., "The Gomberg-Bachmann Reaction of Punnes", <u>J. Heterocyclic Chem.</u> , May-Jun 1987, pp. 859-861, Vol. 24	
	, A31	VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2", 3"- Dideoxyadenosine," <u>J. Am. Chem.</u> <u>Soc.</u> , 1989, pp. 8502-8504, Vol. 111	
	A32	VASU NAIR et al., "Synthesis Of Congeners Of Adenosine Resistant To Deamination By Adenosine Deaminase, " J. Chem. Soc Comm., 1989, pp. 878-879	
	АЗЗ	JAMES L. KELLEY et al., "Synthesis and Structure- Activity Relationships of 2-Substituted-6- (dimetrylamino)- 9- (4-methylbenzyl)-9H-purines with Antirhinovirus Activity," J. Med. Chem., 1989, pp. 218-224, Vol. 32	
	A34	JAMES E. KELLEY et al., "Antiminovirus structure-activity relationships of 6-substituted-8-(4-methylbenzyl)-2- trifluoromethyl-9H-purines," <u>Eur. J. Med. Chem.</u> , 1990, pp. 131-135, Vol. 25	
· -	A35	ROGER J. SCHILLING et al., "A High-Throughput Assay For Cyclic Nucleotide Phosphodiesterases," Analytical Blochemistry, 1994, pp. 154-158, Vol. 215	
	A36	DONALD V. DANIELS et al., "A Semiautomated Method for the Assay of Cyclic Adenosine 5"-Monophosphate Phosphodiesterase," <u>Analytical Biochemistry</u> , 1996, pp. 367-369, Vol. 236	
	A37	JEAN-JACQUES BOURGUIGNON et al., "9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors," <u>J. Med. Chem</u> , 1997, pp. 1768-1770, Vol. 40	
	A38	JAMES L. KELLEY et al., '6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," J. Med. Chem., 1997, pp. 3207-3216, Vol. 40	
	A39	HIROYUKI SAWANISHI et al., "Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle- Condensed Purines", <u>J. Med. Chem.</u> , 1997, pp. 3248-3253, Vol. 40	
	A40	J.E. SOUNNES et al., "Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases", <u>Cell Signal</u> , 1997, pp. 227-238. Vol. 9, No. 3-4	
	A41	MARY ELIZABETH BACH et al., "Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway", Proc. Natt. Acad. Sci. USA, April 1999, pp.5280-5285, Vol. 96	
	A42	ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, Vol 292, No.2	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a velid OMB control number.

Sestitute for form 1449A/PTO

Sheet

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

NI

Application Number 10/067,996
Filing Date February 8, 2002

First Named Inventor Allen T. Hopper
Group Art Unit 1624
Examiner Name Kahsay Habte

(use as many sheets as necessary)

of 2

Attorney Docket Number MEMORY-2

	U.S. PATENT DOCUMENTS										
		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Books Columns Lines Where Relevant .					
Examinar Cit Initials No			of Cited Document	Cited Document MM-DD-YYYY	Pages, Cotumns, Lines, Where Relevant - Passages or Relevant Figures Appear						
	1	20030045533		Liu et al.	3/6/03	·					
											
	 	 									
					-						
		<u> </u>									
-											
		 									
				·							

			FC	REIG	N PATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Initials*	No.'	Office ³		Code ⁵	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
		EP	1 043 324			10/11/2000		
		wo	02/098878			12/12/2002		1
		 		+		-		
	 							
		 		+				
		ļ		-				
				╅──				
				1				

Examiner		Date	·
Signature	•	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are recurred to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, OO NOT SEND FEES

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique distinct designation number. ² See stached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark hee if English language Translation is automated.

						_	
Pleasa	MAR	a olus	sign (+	Abiani (this	hox"	
~~~~	.,,,,,			,		~~~	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

titute for form 1449A/PTO

## NFORMATION DISCLOSURE STATEMENT BY APPLICANT.

(use as many sheets as necessary)

of 2

Complete if Known **Application Number** 10/067,996 Filing Date February 8, 2002 First Named Inventor Allen T. Hopper Group Art Unit 1624 **Examiner Name** Kahsay Habte MEMORY-2 Attorney Docket Number

 ·	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	Japanese Patent Abstract No. 05-001066 dated January 8, 1993		
	Japanese Patent Abstract No. 62-240622 dated October 21, 1987		
	Japanese Patent Abstract No. 62-010085 dated January 19, 1997		
	T. J. Martin, "PDE4 Inhibitors – A Review of the Recent Patent Literature", IDrugs, Vol. 4, No. 3, 2001, pgs 312-338.		
	· · · · · · · · · · · · · · · · · · ·	<del>                                     </del>	
		<u> </u>	

۱	Examiner	Date	· —
ı	Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.